Jade Biosciences (NASDAQ:JBIO) Rating Increased to Hold at Zacks Research

Key Points

• Zacks Research upgraded Jade Biosciences from a "strong sell" to a "hold", while the wider analyst community leans positive with a consensus rating of Moderate Buy and an average price target of $29.50.
• Shares opened at $18.23 with a market cap of about $899 million, 50/200‑day moving averages of $14.68/$13.06 and a 52‑week range of $6.57–$100.10; the company reported Q1 EPS of ($0.11), beating estimates of ($0.45).
• Institutional interest has grown—notable new stakes by Frazier Life Sciences and Aberdeen—while Jade remains a clinical‑stage biotech focused on small‑molecule therapies for inflammatory skin diseases and chronic itch.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Guggenheim upped their price objective on shares of Jade Biosciences from $17.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Lifesci Capital raised Jade Biosciences to a "strong-buy" rating in a research report on Friday, March 6th. BTIG Research lifted their price objective on Jade Biosciences from $28.00 to $39.00 and gave the company a "buy" rating in a research report on Monday, March 16th. William Blair raised Jade Biosciences to a "strong-buy" rating in a research report on Monday, March 9th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Jade Biosciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jade Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Jade Biosciences Stock Performance

Jade Biosciences stock opened at $18.23 on Wednesday. The company has a market capitalization of $899.03 million, a price-to-earnings ratio of -3.96 and a beta of 1.03. The stock has a fifty day moving average of $14.68 and a two-hundred day moving average of $13.06. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $100.10.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last announced its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.34.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Jade Biosciences in the second quarter worth about $17,703,000. Aberdeen Group plc purchased a new stake in shares of Jade Biosciences in the fourth quarter worth about $13,382,000. New York State Common Retirement Fund boosted its position in shares of Jade Biosciences by 4,180.3% in the third quarter. New York State Common Retirement Fund now owns 5,222 shares of the company's stock worth $45,000 after buying an additional 5,100 shares during the period. Corient Private Wealth LLC purchased a new stake in shares of Jade Biosciences in the second quarter worth about $101,000. Finally, Group One Trading LLC boosted its position in shares of Jade Biosciences by 122.9% in the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company's stock worth $65,000 after buying an additional 22,527 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.